{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:16:25Z","timestamp":1792602985094,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Mepolizumab, a monoclonal antibody targeting interleukin-5, is used to treat severe eosinophilic asthma and other eosinophilia-related conditions. Given its growing use, there is a pressing need for the latest data to improve the understanding and management of its adverse events (AEs). This study aimed to investigate the safety of mepolizumab by analyzing the pharmacovigilance database of the US Food and Drug Administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The AE signals associated with mepolizumab from 2015 to 2024 were analyzed and the correlations using reporting ratios (RORs) quantified. Subgroup analyses were conducted to understand AEs in individuals \u2264 18 years of age. We also used time-to-onset (TTO) analysis to examine AE occurrence patterns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 82,478 AE reports linked to mepolizumab therapy were included. Our analysis, involving 24,156 patients, revealed a predominance of female patients, with the highest incidence of AEs occurring in those aged 18\u201365 years. Disproportionality analyses revealed significant signals across various system organ classifications (SOCs), most prominently respiratory, thoracic, and mediastinal disorders (ROR = 5.12, 95% confidence intervals [CI] 5.03\u20135.21), infections and infestations (ROR = 1.86, 95% CI 1.81\u20131.90), and immune system disorders (ROR = 1.14, 95% CI 1.08\u20131.21). The highest ROR was found for asthma crisis (ROR = 104.90, 95% CI 95.31\u2013115.44) at the preferred term (PT) level, and the other notables were coronavirus infection (ROR = 7.33, 95% CI 6.05\u20138.88) and coronavirus disease 2019 (COVID-19) (ROR = 1.34, 95% CI 1.23\u20131.47). A subgroup analysis of patients \u2264 18 years old identified four significant SOC signals, with the highest ROR in respiratory, thoracic, and mediastinal disorders (ROR = 5.28, 95% CI 4.17\u20136.68). PT analysis revealed significant AEs, such as wheezing, bronchospasm, and chest discomfort. TTO analysis revealed that 18.5% of AEs occurred within the first 30 days of treatment. The Weibull shape parameter indicated an \u201cearly failure-type\u201d pattern for mepolizumab-associated AEs, underscoring the need for vigilant monitoring during the initial stages of therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study highlights the importance of post-market surveillance for monitoring the safety of mepolizumab, which revealed significant AE signals, particularly for respiratory diseases, infections, and immune system complications. The association with opportunistic infections, including COVID-19, highlights the need for vigilant surveillance and further research.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1449194","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T04:43:22Z","timestamp":1729831402000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"11","author":[{"given":"Shan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonglian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/all.15754","article-title":"The changing global prevalence of asthma and atopic dermatitis","volume":"78","author":"Denton","year":"2023","journal-title":"Allergy."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3390\/ijerph18031138","article-title":"The exposome approach to decipher the role of multiple environmental and lifestyle determinants in asthma","volume":"18","author":"Guillien","year":"2021","journal-title":"Int J Environ Res Public Health."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1183\/09031936.99.14512109","article-title":"The importance of genetic influences in asthma","volume":"14","author":"Los","year":"1999","journal-title":"Eur Respir J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity."},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2013present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-2600(20)30051-5","article-title":"Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practice","volume":"8","author":"Beasley","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103615","DOI":"10.1016\/j.amjoto.2022.103615","article-title":"Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: a systematic review","volume":"43","author":"Aldajani","year":"2022","journal-title":"Am J Otolaryngol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1280490","DOI":"10.3389\/fphar.2023.1280490","article-title":"A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura","year":"2015","journal-title":"J Pharm Health Care Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2101209","DOI":"10.1183\/13993003.01209-2021","article-title":"Asthma and COVID-19 risk: a systematic review and meta-analysis","volume":"59","author":"Sunjaya","year":"2022","journal-title":"Eur Respir J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1080\/02770903.2021.1888116","article-title":"Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: systematic review and meta-analysis","volume":"59","author":"Sunjaya","year":"2022","journal-title":"J Asthma."},{"key":"B25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaci.2020.05.013","article-title":"ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma-implications for COVID-19","volume":"146","author":"Bradding","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaci.2020.05.051","article-title":"Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype","volume":"146","author":"Camiolo","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","article-title":"Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study","volume":"146","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaci.2021.06.006","article-title":"COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: nationwide real-world evidence","volume":"148","author":"Adir","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1449194\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T13:22:49Z","timestamp":1730985769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1449194\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":28,"alternative-id":["10.3389\/fmed.2024.1449194"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1449194","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"article-number":"1449194"}}